

CLINICAL GUIDELINES ON COVID-19 VACCINATION IN THE PERUVIAN SOCIAL SECURITY

Approximately 127 million of COVID-19 cases have been reported globally. Peru is one of the 20 countries most affected by this pandemic, which has reported 1.52 million of cases and 51 238 deaths by COVID-19 infection until March 28, 2021, and these numbers keep increasing. Faced with this situation, vaccines have been developed to stop the spread of this disease, some of which have been acquired and implemented by different countries. In Peru, until March 23, 2021, agreements for procurement of Sinopharm, Pfizer, and AstraZeneca vaccines were carried out. With these procurements, the Ministry of Health (MINSA in Spanish) has formulated a vaccination prioritization plan, as well as a health directive that establishes the prioritized population and the technical criteria for the vaccination against the COVID-19 in Peru. However, there is uncertainty about indications in specific populations or situations. Thus, the objective of this document is to provide clinical guidelines on procedures, indications, and contraindications of the vaccination against COVID-19, considering the approved vaccines with agreement for procurement by the Peruvian government, in the Peruvian Social Security, EsSalud.